Thyroid Eye Disease (TED) Market Report 2026

The thyroid eye disease (ted) market size has grown strongly in recent years. It will grow from $2.29 billion in 2025 to $2.44 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increasing prevalence of autoimmune thyroid disorders, improved clinical recognition of ted symptoms, wider use of corticosteroid therapies, expansion of ophthalmology services, growing referral rates from endocrinology clinics.

The thyroid eye disease (ted) market size is expected to see strong growth in the next few years. It will grow to $3.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing adoption of novel biologics such as teprotumumab, rising investments in autoimmune disease research, expansion of minimally invasive surgical options, growing focus on quality-of-life outcomes, increasing demand for personalized ted therapies. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising use of combination treatment approaches, growing focus on early disease intervention, expansion of specialized ophthalmic care, enhanced patient-centered treatment models.

The rising prevalence of thyroid disorders is expected to drive growth in the thyroid eye disease (TED) market in the coming years. Thyroid disorders affect the thyroid gland’s function, causing hormone imbalances that can lead to conditions such as hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. Factors contributing to the increase in thyroid disorders include higher iodine intake, autoimmune conditions, genetic predisposition, and improved awareness and diagnostic rates. Thyroid Eye Disease (TED) is a significant complication of Graves’ disease, adding to the overall burden and visibility of thyroid-related conditions. For example, in May 2024, the Canadian Cancer Society, a Canada-based non-profit, reported that approximately 6,600 new thyroid cancer cases are expected in Canada in 2024, with around 280 projected fatalities. Therefore, the rising incidence of thyroid disorders is fueling the growth of the TED market.

Key companies in the thyroid eye disease (TED) market are focusing on innovative therapies, such as monoclonal antibody treatments, to develop more precise and effective options that reduce inflammation, improve proptosis, and enhance patient outcomes. Monoclonal antibody therapies use lab-engineered antibodies designed to mimic the immune system’s ability to target specific cells or pathogens. For instance, in September 2024, Amgen Inc., a US-based biotechnology company, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved TEPEZZA (teprotumumab) for treating active thyroid eye disease (TED), a rare autoimmune disorder that can threaten vision. TEPEZZA is the first and only FDA-approved therapy specifically for TED, offering targeted treatment to reduce inflammation, swelling, and other debilitating symptoms. This approval provides patients in Japan with an effective new option to manage TED, a progressive condition that causes eye bulging, vision impairment, and eye pain.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for an undisclosed amount. Through this acquisition, Amgen aims to strengthen its rare and inflammatory disease portfolio by leveraging Horizon’s key therapies, expanding its global presence, and accelerating innovation to support long-term growth. Horizon Therapeutics plc is an Ireland-based company specializing in rare autoimmune and inflammatory diseases.

Major companies operating in the thyroid eye disease (ted) market are Viridian Therapeutics Inc, Tourmaline Bio Inc, Sling Therapeutics Inc, Immunovant Inc, Hoffmann‑La Roche AG, H Lundbeck A S, Alumis Inc, Changchun GeneScience Pharmaceutical Co Ltd, Minghui Pharmaceutical Inc, Amgen Inc, Crinetics Pharmaceuticals Inc, Ollin Biosciences Inc, Lycia Therapeutics Inc, Inflammasome Therapeutics Inc, Novartis Pharmaceuticals Corp, AdvanceCOR Inc, Worg Pharmaceuticals Inc, AV7 Limited, EVOQ Therapeutics Inc, ValenzaBio Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sanofi SA, Alexion Pharmaceuticals Inc, Septerna Corporation.

North America was the largest region in the thyroid eye disease (TED) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid eye disease (ted) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thyroid eye disease (ted) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the thyroid eye disease market by increasing costs of imported biologics, ophthalmic surgical instruments, imaging systems, and specialty pharmaceuticals used in treatment. Hospitals and specialty eye clinics in North America and Europe are most affected due to dependence on imported therapies, while Asia-Pacific faces higher costs for advanced biologic drugs. These tariffs are raising treatment expenses and influencing therapy accessibility. However, they are also encouraging domestic biologic production, regional clinical research activity, and localized supply of ophthalmic treatment solutions.

The thyroid eye disease (ted) market research report is one of a series of new reports that provides thyroid eye disease (ted) market statistics, including thyroid eye disease (ted) industry global market size, regional shares, competitors with a thyroid eye disease (ted) market share, detailed thyroid eye disease (ted) market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid eye disease (ted) industry. This thyroid eye disease (ted) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Thyroid eye disease (TED), also called Graves’ Orbitopathy, is an autoimmune disorder marked by inflammation and swelling of the tissues surrounding the eyes, often linked to thyroid conditions. TED can lead to symptoms such as bulging eyes, double vision, and eye pain.

The main treatment options for thyroid eye disease (TED) include medical, surgical, and combined medical-surgical approaches. Medical treatment typically involves corticosteroids, immunosuppressive drugs, and biologic therapies to reduce inflammation, manage symptoms, and prevent disease progression. Treatment is tailored according to disease severity, classified as mild, moderate, or severe. Medications used include biologics, small molecules, and others. These therapies are administered through various routes, including oral, intravenous, and subcutaneous methods, and are utilized by end-users such as hospitals, clinics, and other healthcare facilities.

The thyroid eye disease (TED) market includes revenues earned by entities by providing services such as diagnosis services, pharmaceutical services, surgical services, support, and counseling services and related products including thyroid hormone replacement therapy, immunosuppressive drugs, surgical products, and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.